PHARMA SECTOR
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended lower during Muhurat Trading on November 8, snapping a six-session winning streak. Nifty slipped below 25,000 as investors booked profits. However, broader market sentiment remained positive, with 2,716 NSE stocks advancing against 736 declines.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Dalal Street Week Ahead: Nifty bulls come back to life, but 25,000–25,200 zone poses next test
Indian equity markets rallied significantly following the results of the US midterm elections, which were favorable for investors. The Nifty Index saw a large gain and reclaimed important moving averages, indicating improved market sentiment. Some consolidation is expected, as the Index approaches broader resistance levels between 25,000 and 25,200. Various sector indices showed differing momentum as they contrasted against the broader Nifty 500 Index.
Samir Arora backed Helios Mid Cap Fund adds Aurobindo Pharma, 2 others, increase stake in Paytm, MCX and 16 others
Samir Arora-backed Helios Mid Cap Fund added Aurobindo Pharma, Zetwerk and PVR Inox in October, while increasing stakes in Paytm, MCX and 16 other stocks. The fund exited Park Medi World, expanded its portfolio to 77 stocks and reported assets under management of Rs 2,421 crore.
F&O Talk: Nifty’s bullish structure intact after best week in 5 years; Sudeep Shah on HDFC Bank strategy, picks 5 stocks this festive season
Nifty surged 8% to post its strongest weekly gain in five years, supported by improving technical indicators and bullish momentum. SBI Securities’ Sudeep Shah discusses market outlook, HDFC Bank’s rally, mid- and smallcap trends, AI-linked stock risks and sectors showing promising buying opportunities.
Ahead of Market: 10 things that will decide stock market action on Friday
Indian markets staged a powerful rally, with Sensex jumping 2,009 points and Nifty gaining 576 points. Improved global sentiment, easing crude prices, US midterm election results, foreign investor buying and strong Q2 earnings lifted market capitalisation above Rs 500 lakh crore.
- Go To Page 1
Market wrap: Bajaj Finance, Shriram Finance, Apollo Hospital, ONGC top gainers and losers on Nifty and Sensex on Thursday
Indian equity markets staged a strong rally on Thursday, with the Sensex surging over 2,000 points and the Nifty jumping 576 points amid optimism following the US midterm election results. Bajaj Finance, Shriram Finance and M&M led the gainers, while Apollo Hospitals and ONGC featured among the top laggards.
AI, data, cybersecurity lead tech hiring with 30.3% share in September quarter
In India, the demand for roles in AI, data, and cybersecurity within Global Capability Centers (GCCs) has surged, even amid a slight overall hiring decline. AI and data professional roles saw a 14% increase quarter-on-quarter, while cybersecurity positions grew by 12%. Notably, tier-2 cities like Coimbatore achieved a remarkable 30% growth. By 2030, the GCC workforce in India is projected to reach between 2.7 and 2.8 million.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
Global Market Today: Asian stocks rise as oil slides after US midterm elections
Benchmark indexes rose in Japan and Australia, pushing the MSCI Asia Pacific Index up by 0.3%. That was after the S&P 500 Index jumped 1.6%, its biggest gain in three months, and the tech-heavy Nasdaq 100 climbed 0.9%. South Korea was the outlier, with the Kospi Index dropping 2.7%, reflecting investor concerns over the future of data-center development and losses in US chip stocks.
Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco
Indian equity markets have enjoyed a remarkable stretch, registering gains for five consecutive sessions. The Nifty 50 index showed impressive growth, sparking optimism for a breakout beyond 24,000. Companies like Lenskart, Aurobindo Pharma, and BSE are in the spotlight as they report positive earnings. Experts advise keeping an eye on the support levels as the bullish trend persists.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Stocks in news: NSE, BSE, SBI, Happiest Minds, MCX, IEX and Minda Corp
The Indian stock market continues its upward momentum, with the Nifty 50 showing a robust rally and hitting significant resistance levels. Major players like NSE and SBI have posted remarkable quarterly results, illustrating their strong profitability and revenue growth. Firms such as Happiest Minds Technologies and the Multi Commodity Exchange of India contributed positively to the market's performance.
India has never allowed genetically modified products' import, won't do in future: Piyush Goyal
India continues to maintain a strict policy against the import of genetically modified products, as stated by Minister Piyush Goyal. He highlighted that the dairy sector remains particularly sensitive and has not been opened in trade agreements. Goyal emphasized India's commitment to protecting its agricultural and fisheries sectors while seeking preferential market access for textiles and pharmaceuticals.
India has never allowed import of GM products, will never open dairy sector: Piyush Goyal
Commerce and Industry Minister Piyush Goyal emphasized India’s commitment to safeguarding its dairy sector from free trade agreement pressures. He reiterated the nation's opposition to imports of genetically modified products, considering them sensitive. Goyal mentioned efforts to unlock new employment opportunities and promote domestic agriculture for competitive exports.
Beyond tech: Kotak MF’s Shibani Kurian on India’s next innovation-led winners
Innovation-led investment opportunities in India are extending well beyond technology, with healthcare, auto components and industrials emerging as key areas of interest, according to Shibani Kurian, Head of Equity Research and Senior Fund Manager at Kotak Mahindra AMC. “Innovation can be seen across sectors and not necessarily limited to technology,” she said.
Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza
As per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue. This makes today the last day to buy the stock to be eligible for the bonus shares.
Market wrap: RIL, Tata Steel, Infosys, ICICI Bank top gainers and losers on Nifty and Sensex on Monday
Indian markets rallied sharply, with Sensex gaining 1.66% to 75,693 and Nifty rising 1.68% to 23,441. Strong quarterly earnings lifted investor sentiment, led by Reliance Industries, metals and oil and gas stocks, while market breadth remained positive.
Technology funds top October returns with gains of up to 10%. Is it the right time to invest?
Technology mutual funds topped October returns, with the nine best-performing schemes delivering gains of up to 9.78%, an ETMutualFunds analysis showed. HDFC Technology Fund led the chart, followed by Kotak Technology Fund and Tata Digital India Fund. Of the nearly 626 funds analysed, all nine top performers belonged to the technology sector, reflecting a strong monthly recovery in the segment.
Diwali investment picks 2026: 10 fund managers reveal promising opportunities and risks to watch
This Diwali, investment experts advise a strategic approach focused on asset allocation rather than luring high-growth stocks. Sectors like banking, financial services, and premium goods present promising opportunities. While gold should only occupy a small fraction of a diversified portfolio for risk management, short-duration debt funds gain favour as interest rates shift. Maintaining discipline and patience is essential for long-term investment success.
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a year
With Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases an astonishing gain of 4,657%, while Axis Solution follows closely with 1,081%. Other strong performers are Sterlite Technologies and Cupid, each demonstrating impressive growth. Analysts are hopeful for a market rebound thanks to falling crude oil prices, which could positively impact sectors such as automotive, capital goods, and pharmaceuticals.
Climate platform Two Point O raises $10 million led by Transition Venture Capital
The company plans to enter battery energy storage while expanding its existing offerings in solar power, energy efficiency, and wastewater treatment. It will also target customers in sectors such as data centres, automobile manufacturing, pharmaceuticals, and healthcare, where energy and water consumption are significant operating costs.
India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs
Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.
F&O Talk: Big break above 23,200 can open doors for 23,500 for Nifty; Sudeep Shah picks 6 stocks ahead of Diwali
Nifty could extend its recovery towards 23,500 if it decisively breaks above the 23,150–23,200 resistance zone, says SBI Securities' Sudeep Shah. He also shares his outlook on IT, midcap and smallcap indices, sector trends and six stocks, including TVS Motor, Coforge and ICICI Bank, ahead of Diwali.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Dalal Street Weak Ahead: Nifty stands on firmer footing, but can it break past 23,450?
The Nifty gained 2% last week, recovering above the crucial 200-week moving average at 22,700. While easing volatility and buying at lower levels support the rebound, bearish momentum indicators suggest caution. Analysts identify 23,300–23,450 as immediate resistance and 22,750–22,525 as key support for the coming week.
Market wrap: Shriram Finance, Nestle India, Trent, InterGlobe top gainers and losers on Nifty and Sensex on Friday
The Nifty 50 rose 0.51% to close at 23,053.10 on Friday, while the Sensex gained 308 points to 74,459.53. Trent and InterGlobe led the gainers, while Shriram Finance and Nestle India topped the Nifty losers. Broader markets remained weak, with midcap and smallcap indices falling up to 2%.
Sensex rises 308 points, Nifty above 23,000 even as broader markets crash. Will D-Street bulls extend recovery next week?
Indian market indices Sensex and Nifty ended the week on a high note, each climbing by up to 0.5%. Even as the broader market suffered losses, standout performers like Trent and IndiGo flourished thanks to positive earnings. The Nifty IT index was a highlight, soaring over 2%, while Nifty Consumer Durables fell nearly 2%.
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.
Load More
